Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)

Inclusion criteria

• . Signed, informed consent must be obtained prior to any study specific procedures.
• . Subjects with a histologically confirmed diagnosis of MDS by FAB criteria, including both MDS and RAEB-T (AML with 20-30% blasts and multilineage dysplasia) by World Health Organization (WHO) classification are eligible.
• . Patients must have completed at least 4 cycles of hypomethylating agent therapy (e.g azacitidine or decitabine) with failure to achieve at least a partial response, or with the presence of ongoing cytopenias per International Working Group (IWG) (platelet count \< 100x10\^9/L, hemoglobin \<11g/L or Absolute Neutrophil Count (ANC) \<1x10\^9/L). Patients with progressive disease on HMA-therapy prior to this time point are also eligible at the time of documented progression. Therapy with decitabine analogs (i.e. SGI-110) will be considered as decitabine for the purposes of this study.
• . Platelet count \<100x10\^9/L
• . Low, intermediate-1, intermediate-2 or High-risk category by International Prognostic Scoring System (IPSS)
• . Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
• . Adequate liver function, as evidenced by a serum bilirubin \</=2x the ULN (except for patients with a confirmed diagnosis of Gilbert's Disease) and an Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) \</=3x the laboratory Upper Limit of Normal (ULN).
• . Serum creatinine \</=2x upper limit of normal

Exclusion criteria